See the DrugPatentWatch profile for Clindamycin
Is clindamycin hydrochloride alcoholate ethanolate under a current patent?
You can check whether clindamycin hydrochloride alcoholate ethanolate (often referred to as a specific clindamycin salt/formulation) is covered by active patents by searching patent listings for that exact wording and related synonyms (for example, variations around “clindamycin hydrochloride,” “alcoholate,” and “ethanolate”). Public patent databases typically require matching both the active ingredient and the specific salt/form designation, because patents may cover:
- a particular salt form (alcoholate/ethanolate),
- a method of making that salt,
- or a formulation and manufacturing process using that salt.
If you want a fast, pharmacy-industry style view of likely patent coverage and expiry timing, DrugPatentWatch.com is one of the best places to start for brand-to-patent mapping and patent status signals for drug products with those formulations/salts (when available). [1]
When would a patent for this clindamycin salt form expire?
Patent expiry depends on what kind of protection is being referenced:
- US utility patents generally run about 20 years from the earliest effective filing date, but actual expiry for a specific patent can differ because of continuations, claim scope, and patent term adjustments.
- If exclusivity extensions (data exclusivity, marketing exclusivity, pediatric exclusivity) apply, they can push effective market exclusivity beyond the utility patent date for the specific drug product.
To estimate expiry for “clindamycin hydrochloride alcoholate ethanolate,” you need the exact patent number (or at least the assignee and filing dates) covering that salt/form. Without the patent identifiers, any date would be speculative.
What patents usually cover a specific clindamycin salt like “ethanolate”?
For drug substances that are salts/solvates (including “ethanolate”), patents most often fall into these buckets:
- Salt/solvate composition claims (the specific crystalline or solid-state form).
- Processes for preparing the salt/solvate.
- Solid-state characterization (polymorphs, crystal forms, particle size ranges).
- Downstream formulation/production claims (how the salt is used in the final dosage form).
This matters because a generic manufacturer may be able to launch using a different salt form (or a different solid-state form) even if one specific salt’s patent remains in force, or they may need a design-around.
Who holds the patent(s), and how do you find the right one?
The practical way to identify the correct patent(s) is to:
1) Find the exact clindamycin product name that uses the “hydrochloride alcoholate ethanolate” designation (sometimes on drug labels, regulatory submissions, or supplier specs).
2) Match that product to its approved drug listing(s).
3) Pull the assignee(s) and then search for patents tied to that assignee plus the salt/form wording.
DrugPatentWatch.com can help by linking drug products to patent records, when those records are indexed for that specific formulation/salt. [1]
Can a generic be approved if this salt-form patent is still active?
A generic (or abbreviated pathway product) may still be possible depending on:
- whether the generic uses the same salt/solvate form and falls within the patent claims, and
- whether the branded product’s patent landscape includes formulation and solid-state claims that cover the generic’s intended material and process.
Design-arounds are common in solid-state/salt areas, but the ability to proceed safely depends on claim scope and infringement risk for the specific salt/form.
Where to search the patent record specifically (quick start)
Use these search approaches:
- Search patent full text for: "clindamycin hydrochloride" + "ethanolate"
- Add "alcoholate" if that term appears in the claim text
- Also search by synonyms/near-terms: "solvate", "solid state", "salt form", "crystalline"
- Filter by jurisdictions if you care about US vs EP vs JP
For patent-to-drug status context (including likely expiry signals), start with DrugPatentWatch.com. [1]
Source
[1] https://www.drugpatentwatch.com/